NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

主動植入式醫療設備(AIMD)市場 - 預測(2021年∼2026年)

Active Implantable Medical Devices (AIMD) Market - Forecasts from 2021 to 2026

出版商 Knowledge Sourcing Intelligence 商品編碼 1023177
出版日期 內容資訊 英文 114 Pages
商品交期: 最快1-2個工作天內
價格
主動植入式醫療設備(AIMD)市場 - 預測(2021年∼2026年) Active Implantable Medical Devices (AIMD) Market - Forecasts from 2021 to 2026
出版日期: 2021年07月05日內容資訊: 英文 114 Pages
簡介

全球主動植入式醫療設備的市場規模,預計從2019年的238億1,800萬美元到2026年達到368億4,500萬美元,在預期期間中預計以6.43%的年複合成長率發展。

由於全球心血管疾病患病率不斷上升,預計未來幾年市場將激增。心血管疾病是世界範圍內導致死亡的主要原因之一。根據世界衛生組織提供的資料,2019年估計有1790萬人死於心血管疾病。其中約85%的死亡歸因於中風和心臟病發作。全球估計有11.3億人患有高血壓,高血壓已成為導致大腦、心臟、腎臟與其他相關問題的主要原因。預計在未來一段時間內,某些設備(例如植入式心律轉復除顫器)的需求將顯著增加。

本報告提供主動植入式醫療設備的市場調查,市場概要,市場成長要素與阻礙因素,各產品、各終端用戶、各地區的分析,主要企業狀況和競爭情形等資訊。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 前提條件

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 波特的五力分析
    • 供給企業的交易
    • 購買企業的交易
    • 新加入業者的威脅
    • 替代品的威脅
    • 產業的競爭企業間的競爭關係
  • 產業的價值鏈分析

第5章 各產品:主動植入式醫療設備市場分析

  • 簡介
  • 輔助人工心臟
  • 神經刺激設備
  • 植入式心臟心律調節器
  • 人工電子耳
  • 其他

第6章 各終端用戶:主動植入式醫療設備市場分析

  • 簡介
  • 醫院和診所
  • 門診病人手術中心

第7章 各地區:主動植入式醫療設備市場分析

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 法國
    • 德國
    • 義大利
    • 其他
  • 中東和非洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 泰國
    • 台灣
    • 印尼
    • 其他

第8章 競爭環境與分析

  • 主要企業策略分析
  • 新興企業和市場收益性
  • 合併,收購,協定,共同研究
  • 供應商競爭力 矩陣

第9章 企業簡介

  • Sonova Holding AG
  • Medtronic
  • Abbott
  • Lifetech Scientific
  • Boston Scientific Corporation
  • Cochlear Ltd.
  • MED-EL
  • BIOTRONIK SE & CO. KG
  • LivaNova PLC
  • Advanced Bionics AG
目錄
Product Code: KSI061611637

The global active implantable medical devices market is expected to grow at a CAGR of 6.43% over the forecast period to reach a market size of US$36.845 billion in 2026 from US$23.818 billion in 2019. As per The Active Implantable Medical Device (AIMD) Directive, an active implantable medical device is "any active medical device which is intended to be totally or partially introduced, surgically or medically, into the human body or by medical intervention into a natural orifice, and which is intended to remain after the procedure". An implantable pacemaker, cochlear implants, ventricular assist devices, neurostimulators are some of the active implantable medical devices. Active implantable medical devices fall into the highest risk categories of medical devices listing by the U.S. Food & Drug Administration (FDA). The growth in the market may be attributed to the rising prevalence of cardiovascular and neurological disorders across the globe. Rising investments and funds by the companies to develop technologically advanced products will also boost the market for AIMD during the given forecast period. However, strict regulatory policies regarding the AIMD and the high cost of the devices may restrain the market growth during the given time frame. Major companies have been making significant developments in the market, in the past few years. With the increasing investment in innovation, research and development, and infrastructure, the market is expected to surge at an exponential rate in the coming years.

Increasing cardiovascular diseases.

The market is expected to surge in the coming years, due to the rising prevalence of cardiovascular diseases, globally. Cardiovascular diseases are one of the leading causes of death, worldwide. According to the data given by the World Health Organisation, an estimated number of 17.9 million people had died from cardiovascular diseases in the year 2019. Around 85% of these deaths were attributed to stroke and heart attack. An estimated 1.13 billion people, globally, have been suffering from hypertension, which has become a major cause of brain, heart, kidney, and other related problems. Some of the devices, such as implantable cardioverter-defibrillator have been expected to show a significant surge in the demand, in the coming period. It is a device that is usually placed on the chest, to detect irregular heartbeats and monitor heart rhythm. Major companies have been making significant developments in the market. For instance, Medtronic, one of the major players in the market, provides implantable cardioverter defibrillators to their customers. The company's model and devices, known as Cobalt XT IDDs, are enabled with advanced BlueSync technology, which allows for app-based monitoring and tablet-based monitoring. These developments are expected to enhance the overall market growth, in the coming years.

Increasing government regulations.

The European Union had announced that it had published an updated list of regulations and standards, that would be used to showcase and demonstrate conformity with required and essential requirements of its major flagship derivate known Directive 90/385/EEC, which are related to active implantable devices. According to the directive given by the European Union, an active medical device would be a major functioning source of electrical energy or any other source of energy, but different than directly released by the gravity or human body. Moreover, increasing regulations in North America, Asia Pacific, and other regions are also expected to provide a challenge to the overall market growth.

Latest Developments.

Major companies, research institutions, and organizations have been making considerable investments, intending to develop novel, advanced, and innovative active implantable medical devices for their customers.

  • In May 2021, Researchers at the Columbia University announced that they had developed a novel single-chip device that takes less than 0.1 mm3. It had been one of the smallest systems, ever developed and designed. The researchers stated that the device would be injected into humans, to monitor certain biological parameters. The major goal of this research has been to replace larger implantable sensors, that require several packaging, chips, batteries, external transducers, and wires. This development is expected to have a positive impact on the market, in the coming years.
  • In June 2021, FineHeart S.A., a preclinical medical device firm, announced that they had completed a EUR15 million funding round. The company had been developed an implantable cardiac output management system, called FLOWMAKER, to address the need of patients, that are suffering from severe heart failure. The company has also stated that the novel funding would allow preparing for first in human clinical trials in the year 2022.

North America is expected to have a major share.

North American region is expected to have a major share in the market, due to the rise in the number of active implantable medical device start-ups, the presence of some of the major players in the region, and increased cardiovascular problems. Other regions are also expected to exhibit higher potential in the overall market. With the rise in the geriatric population and surging cardiovascular concerns, Europe is expected to register significant CAGR growth, during the forecast period. Countries like Germany and Italy are expected to emerge as a major potential region, in the coming years.

Market Segmentation:

  • By Type
  • Ventricular Assist Devices
  • Neurostimulators
  • Implantable Cardiac Pacemakers
  • Cochlear Implants
  • Others
  • By End-User
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Thailand
  • Taiwan
  • Indonesia
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Active Implantable Medical Devices Market Analysis, By Product

  • 5.1. Introduction
  • 5.2. Ventricular Assist Devices
  • 5.3. Neurostimulators
  • 5.4. Implantable Cardiac Pacemakers
  • 5.5. Cochlear Implants
  • 5.6. Others

6. Active Implantable Medical Devices Market Analysis, By End-User

  • 6.1. Introduction
  • 6.2. Hospitals & Clinics
  • 6.3. Ambulatory Surgical Centers

7. Active Implantable Medical Devices Market Analysis, By Geography

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. UK
    • 7.4.2. France
    • 7.4.3. Germany
    • 7.4.4. Italy
    • 7.4.5. Others
  • 7.5. The Middle East and Africa
  • 7.6. Asia Pacific
    • 7.6.1. Japan
    • 7.6.2. China
    • 7.6.3. India
    • 7.6.4. Thailand
    • 7.6.5. Taiwan
    • 7.6.6. Indonesia
    • 7.6.7. Others

8. Competitive Environment and Analysis

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. Company Profiles

  • 9.1. Sonova Holding AG
  • 9.2. Medtronic
  • 9.3. Abbott
  • 9.4. Lifetech Scientific
  • 9.5. Boston Scientific Corporation
  • 9.6. Cochlear Ltd.
  • 9.7. MED-EL
  • 9.8. BIOTRONIK SE & CO. KG
  • 9.9. LivaNova PLC
  • 9.10. Advanced Bionics AG